ScholarLens Back to search
2017•Journal watchRequires access

Rivaroxaban vs. Aspirin to Prevent Recurrent Venous Thromboembolism

Allan S. Brett

Open publisher page 0 citations

Abstract

The duration of guideline-recommended antithrombotic therapy for patients with venous thromboembolism (VTE) ranges from 3 months to indefinite, depending on whether the VTE is provoked or unprovoked and on patients' bleeding risks (NEJM JW Emerg Med Feb 2016 and Chest 2016; 149:315). For long-term prevention of recurrent VTE, options include warfarin, direct-acting oral anticoagulants, and aspirin; among the anticoagulants, guidelines recommend direct-acting anticoagulants over warfarin, unless substantial renal impairment …

About this research paper

What this paper is about

The duration of guideline-recommended antithrombotic therapy for patients with venous thromboembolism (VTE) ranges from 3 months to indefinite, depending on whether the VTE is provoked or unprovoked and on patients' bleeding risks (NEJM JW Emerg Med Feb 2016 and Chest 2016; 149:315). For long-term prevention of recurrent VTE, options include warfarin, direct-acting oral anticoagulants, and aspirin; among the anticoagulants, guidelines recommend direct-acting anticoagulants over warfarin, unless substantial renal impairment …

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The duration of guideline-recommended antithrombotic therapy for patients with venous thromboembolism (VTE) ranges from 3 months to indefinite, depending on whether the VTE is provoked or unprovoked and on patients' bleeding risks (NEJM JW Emerg Med Feb 2016 and Chest 2016; 149:315). For long-term prevention of recurrent VTE, options include warfarin, direct-acting oral anticoagulants, and aspirin; among the anticoagulants, guidelines recommend direct-acting anticoagulants over warfarin, unless substantial renal impairment …

Key concepts: Medicine, Rivaroxaban, Aspirin, Warfarin, Venous thromboembolism, Antithrombotic, Guideline, Apixaban

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Rivaroxaban vs. Aspirin to Prevent Recurrent Venous Thromboembolism — Research Paper | ScholarLens